CD33 and neoplasm: Interestingly, aITGB2 expression remained high (greater than 95%) in the CD33/CD45-positive tumor population in bone marrow, including single-or fractionated-dose [225Ac]Macropa-PEG4-7065 groups (Figure 6E–F, S22A–B), [225Ac]DOTA-anti-CD33 (Figure 6G, S22C–D), [225Ac]Macropa-PEG4-IgG (Figure 6H, S22E–F), saline + IgG (Figure 6I, S22G–H) injected groups.